Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-cldn-5 antibody, and drug containing said antibody

An antibody, N-terminal technology, applied in the field of anti-CLDN-5 antibody and drugs containing the antibody, can solve the problems of low binding specificity, undisclosed, difficult development of blood-brain barrier regulation technology, etc.

Active Publication Date: 2019-12-24
OSAKA UNIV +2
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these molecules have the problem of low binding specificity to CLDN-5 and binding to other CLDN molecules. Therefore, it is considered that the development of blood-brain barrier regulation technology using these molecules is very important from the perspective of enhancing barrier regulation activity and reducing side effects. difficulty
As another example, there are reports on peptides and antibodies that regulate cell adhesion of CLDN family molecules, but this report does not disclose proven data on the regulation of the blood-brain barrier by anti-CLDN-5 antibodies (Patent Document 1)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cldn-5 antibody, and drug containing said antibody
  • Anti-cldn-5 antibody, and drug containing said antibody
  • Anti-cldn-5 antibody, and drug containing said antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0599] Example 1) Antibody production

Embodiment 1-1

[0600] Example 1-1) cell fusion

[0601] A DNA fragment comprising the coding sequence of wild-type human CLDN-5 protein (SEQ ID NO: 27) was inserted into a protein expression vector for mammalian cells, pcDNA3.1 (Thermo Fisher Scientific, V79020), to prepare a plasmid for immunization. Subcutaneous immunization was performed using the prepared plasmid for immunization. Through immunization, BXSB mice and Wistar rat individuals whose serum antibodies were elevated were finally immunized. After the final immunization, lymph node cells were collected from the animal according to a conventional method, and were subjected to cell fusion with mouse myeloma cells (P3U1). Seed the fused cells on ten 96-well plates in Medium 1* at 37°C, 10% CO 2 cultured for 10 days.

[0602] *Medium 1: Hybridoma SFM (Thermo Fisher Scientific, 12045084) + 1x BMcondimed H1 Hybridoma cloning supplement (Roche, 1088947), 1x HAT supplement (ThermoFisher Scientific, 21060017), 1x penicillin and strept...

Embodiment 1-2

[0603] Example 1-2) Preparation of Cells for Screening

[0604]A DNA fragment comprising the coding sequence of wild-type human CLDN-5 protein (SEQ ID NO: 27) was inserted into pCX4pur vector (manufactured by Osaka Bioscience Institute) to obtain a vector for retrovirus production. Inoculate 0.5×10 in each well of a 12-well plate 5 Packaging cells (Phoenix A cells) of 10 cells were cultured for 24 hours. Then, 0.5 μg of pCL ampho vector and 0.5 μg of retrovirus production vector were transfected into phoenix A cells using 3 μL of X-treme GENE HP DNA (Roche Diagnosis, 06366244001). The medium was changed after 24 hours and cultured for a further 24 hours. The culture supernatant containing the retrovirus was collected, filtered through a filter with a pore size of 0.45 μm to remove foreign substances, and polybrene (SigmaAldrich, H9268-5G) was added thereto to obtain 8 μg / mL. Using the obtained solution, human fibrosarcoma-derived cells (HT-1080 cells) were cultured for 24...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to View More

Abstract

The problem of providing a novel molecule having high specificity to CLDN-5 and capable of recognizing an extracellular domain of CLDN-5 can be solved by an antibody capable of specifically recognizing the three-dimensional structure or the primary structure of an extracellular domain of Claudin-5 protein.

Description

technical field [0001] The present invention relates to anti-CLDN-5 antibody and medicine containing the antibody. More specifically, it relates to an antibody that recognizes the extracellular region of CLDN-5, a drug for regulating the blood-brain barrier, and the like. Background technique [0002] The blood-brain barrier is a mechanism that limits the exchange of substances between the blood and the brain, and plays an important role in protecting the brain from foreign substances. On the other hand, since the blood-brain barrier prevents the delivery of intravenously administered drugs to the brain, it has become a major obstacle in the development of drugs for treating brain diseases. The function of the blood-brain barrier is due to the highly tight junctions formed between the capillary endothelial cells of the brain, which are quite different from the gaps between the capillary endothelial cells of other organs that allow substances to permeate. So far, a method o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61K47/68A61P43/00C07K16/46C12N1/15C12N1/19C12N1/21C12N5/10C12N5/12C12N15/13
CPCA61P43/00C07K16/28A61P25/00C12N2510/02C07K2317/34C07K2317/33C07K2317/92G01N33/68A61K2039/505G01N2333/705C07K2317/565
Inventor 近藤昌夫八木清仁土井健史冈田欣晃桥本洋佑泽崎达也竹田浩之远藤幸喜田村真纪
Owner OSAKA UNIV